The MA agreement has delivered outcomes on biosimilars, second brands and establishes a potential relationship between post-market reviews and statutory price reductions. GBMA has secured an extension to its existing agreement and a grant from government to conduct biosimilar education targeting healthcare professionals.
New Stories
-
Mayne officially opens US facility
April 20, 2018 - - Latest News -
The question is how and why now?
April 20, 2018 - - Latest News -
New report show rebates average 44% in New Zealand
April 20, 2018 - - Latest News -
Merck sells consumer health business
April 20, 2018 - - Latest News -
Shire rejects third bid from Takeda
April 20, 2018 - - Latest News -
PBS listing process descends into farce
April 19, 2018 - - Latest News -
A serious industry deserving of serious decisions
April 19, 2018 - - Comment